| INTENDED USE |
IVD |
| SPECIES REACTIVITY |
Human |
| SOURCE |
Mouse Monoclonal |
| CLONE |
BC2 |
| ISOTYPE |
IgG1/kappa |
| ANTIGEN |
CD31 |
| LOCALIZATION |
Cytoplasmic/membrane |
| POSITIVE CONTROL |
Tonsil, angiosarcoma, or colon
cancer |
CD31 recognizes a 100kDA glycoprotein in endothelial cells and
130kD in platelets. It reacts weakly with mantle zone B-cells, peripheral
T-cells, and neutrophils. CD31 can detect vascular endothelium associated
antigen and has been used as a marker for benign and malignant human vascular
disorders, myeloid leukemia infiltrates and megakaryocytes in normal bone
marrow. When compared to Factor VIII and CD34 antibodies, studies have shown
CD31 to be a superior marker for angiogenesis. CD31 has been used to
measure angiogenesis, which reportedly predicts tumor recurrence. CD31 used in a
panel with CD34 and Factor VIII has also been used to mark Kaposi’s sarcoma and
angiosarcomas. Other studies have also indicated that CD31 and CD34 can be used
as markers for myeloid progenitor cells that recognize different subsets of
myeloid leukemia infiltrates (granular
sarcomas).